Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 176,900 shares of the stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the completion of the sale, the chief operating officer now owns 668,680 shares of the company’s stock, valued at approximately $7,903,797.60. The trade was a 20.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Stock Up 3.5 %

Shares of ROIV traded up $0.40 during trading on Tuesday, reaching $11.83. 4,205,813 shares of the company traded hands, compared to its average volume of 5,754,317. The stock has a 50-day simple moving average of $11.91 and a 200-day simple moving average of $11.55. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The stock has a market cap of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25.

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Bank of America increased their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Institutional Trading of Roivant Sciences

Several institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in Roivant Sciences during the second quarter worth $34,000. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences in the 3rd quarter valued at $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences during the 2nd quarter worth about $36,000. US Bancorp DE boosted its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Finally, Quarry LP acquired a new position in Roivant Sciences in the 2nd quarter valued at about $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.